PPBT Earnings & Financial Statements
Purple Biotech Ltd.
$1.23
-$0.13(-9.56%)
41
Overall
80
Value
20
Tech
23
Quality
Market Cap
$2.00M
Volume
53.19K
52W Range
$1.16 - $14.10
Target Price
$17.00
PPBT earnings and financial statements: Purple Biotech Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PPBT Annual Financial Statements
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | - | - | $92.0K | - | $29.00M |
| Cost of revenue | - | - | - | $212.0K | - |
| Operating income | -$10.80M | -$22.27M | -$22.58M | -$18.15M | -$13.30M |
| EBITDA | -$6.61M | -$17.59M | -$21.49M | -$17.52M | -$28.41M |
| Net income | -$7.24M | -$19.88M | -$21.67M | $37.58M | -$28.00M |
| EPS (diluted) | $4.99 | $17.96 | - | $8.00 | $488.00 |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | $37.04M | $44.30M | $54.62M | $70.20M | $83.80M |
| Total liabilities | $4.13M | $10.01M | $7.52M | $5.09M | $4.05M |
| Shareholders’ equity | $32.86M | $34.21M | $46.91M | $64.83M | $79.39M |
| Cash and equivalents | $7.40M | $14.01M | $15.03M | $187.0K | $11.25M |
| Long-term debt | - | $163.0K | $321.0K | $550.0K | $688.0K |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$14.37M | -$19.93M | -$16.73M | -$374.0K | $1.71M |
| Capital expenditure | - | - | -$228.0K | -$115.0K | -$156.0K |
| Free cash flow | -$14.37M | -$19.93M | $5.64M | -$489.0K | $1.55M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PPBT | $1.23 | -9.6% | 53.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |